同型半胱氨酸调控miRNA在心血管疾病中的作用研究进展

同型半胱氨酸(Hcy)是由蛋氨酸代谢生成的中间代谢产物,大量研究发现Hcy与心血管疾病有很大关系。微小RNA(miRNA)是一大类短链非编码RNA,已在多种疾病中证实miRNA失调可导致疾病的发生发展,比如免疫紊乱、糖尿病、癫痫、癌症等。目前miRNA因其在心血管系统中的关键作用而被认为是心血管疾病的新治疗策略。当前研究已证实Hcy与miRNA均是心血管疾病的危险因素,Hcy可通过调控miRNA影响心血管疾病,miRNA也可能对Hcy引起相应变化。但Hcy与miRNA的相互影响在心血管疾病中的作用还有待明确。本文简要综述了Hcy调控miRNA在心血管疾病中的作用进展及其潜在的临床应用价值。

Research progress on the role of Homocysteine regulated miRNA in cardiovascular diseases

Homocysteine (Hcy) is an intermediate metabolite of methionine metabolism, and a large number of studies have found that Hcy is closely related to cardiovascular diseases. MicroRNA(miRNA) is a large class of short-chain non-coding RNA, it has been confirmed in a variety of diseases that miRNA disorder can lead to disease progression, such as immune disorders, diabetes, epilepsy, cancer, etc. At present, miRNA is considered as a new treatment strategy for cardiovascular diseases due to its crucial role in the cardiovascular system. The current study has confirmed that both Hcy and miRNA are risk factors for cardiovascular disease, but the role of Hcy and miRNA interaction in cardiovascular disease remains to be elucidated. This paper briefly reviews the progress and potential clinical application of Hcy regulated miRNA in cardiovascular diseases.